PDCD1 and neoplasm: Importantly, further research has emphasized improved response and survival rates when combining anti-CTLA-4 and anti-PD-1 therapy (130), leading to the approval of ipilimumab plus nivolumab in BRAF wild-type melanoma in 2015 and regardless of BRAF tumor subtype in 2016 (131).